Copyright 2011 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.2011
In the November 22, 2010, issue, Shebah et al1 presented emergency department (ED) visit data for hemorrhage-related adverse drug events (ADEs) associated with dual antiplatelet therapy (DAT) and warfarin therapy. They found that bleeding and its associated risk can be significant. In the “best case scenario,” that of controlled clinical trials, antiplatelet and/or anticoagulant agents, alone or in combination, leads to bleeding.2-4 These and similar agent classes are known to cause mild to severe bleeding depending on risk factors.5 We treat a large population of patients 70 years or older at our institution—a 180-bed, not-for-profit community teaching hospital, an academic affiliate of a large medical school and a member of a major health care system. The hospital provides residency training programs, continuing medical education, and experiential programs for different health care professionals. In 2009, the hospital had 38 584 ED visits, with a 14% admission rate and 10 789 inpatient stays. In 2010 (through October 30), there were 33 498 ED visits (a 13% admission rate) and 9321 inpatient stays.
Kaufman MB, Alberto NA, Bailey DS. Bleeding Associated With Antiplatelet Agents and Warfarin Therapy in the Emergency Department. Arch Intern Med. 2011;171(12):1126. doi:10.1001/archinternmed.2011.265
Customize your JAMA Network experience by selecting one or more topics from the list below.